2022
Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance
Ugarte-Gil M, Alarcón G, Izadi Z, Duarte-García A, Reátegui-Sokolova C, Clarke A, Wise L, Pons-Estel G, Santos M, Bernatsky S, Ribeiro S, Al Emadi S, Sparks J, Hsu T, Patel N, Gilbert E, Valenzuela-Almada M, Jönsen A, Landolfi G, Fredi M, Goulenok T, Devaux M, Mariette X, Queyrel V, Romão V, Sequeira G, Hasseli R, Hoyer B, Voll R, Specker C, Baez R, Castro-Coello V, Ficco H, Neto E, Ferreira G, Monticielo O, Sirotich E, Liew J, Hausmann J, Sufka P, Grainger R, Bhana S, Costello W, Wallace Z, Jacobsohn L, Taylor T, Ja C, Strangfeld A, Mateus E, Hyrich K, Carmona L, Lawson-Tovey S, Kearsley-Fleet L, Schäfer M, Machado P, Robinson P, Gianfrancesco M, Yazdany J. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. Annals Of The Rheumatic Diseases 2022, 81: 970-978. PMID: 35172961, PMCID: PMC8882632, DOI: 10.1136/annrheumdis-2021-221636.Peer-Reviewed Original ResearchMeSH KeywordsCOVID-19HumansLupus Erythematosus, SystemicMalePrednisoneRheumatologySeverity of Illness IndexConceptsSystemic lupus erythematosusCOVID-19 outcomesSevere outcomesDisease activityLupus erythematosusHigher SLE disease activityActive systemic lupus erythematosusMultivariable ordinal logistic regression modelsSevere COVID-19 outcomesPoor COVID-19 outcomesSLE disease activitySex-adjusted modelsMore severe outcomesCOVID-19 severityCOVID-19Logistic regression modelsOrdinal logistic regression modelsPrednisone doseMale sexGlobal RegistryWorse outcomesMultivariable modelCurrent treatmentComorbiditiesOlder age
2020
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
Gianfrancesco M, Hyrich K, Al-Adely S, Carmona L, Danila M, Gossec L, Izadi Z, Jacobsohn L, Katz P, Lawson-Tovey S, Mateus E, Rush S, Schmajuk G, Simard J, Strangfeld A, Trupin L, Wysham K, Bhana S, Costello W, Grainger R, Hausmann J, Liew J, Sirotich E, Sufka P, Wallace Z, Yazdany J, Machado P, Robinson P. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals Of The Rheumatic Diseases 2020, 79: 859-866. PMID: 32471903, PMCID: PMC7299648, DOI: 10.1136/annrheumdis-2020-217871.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnti-Inflammatory Agents, Non-SteroidalAntimalarialsAntirheumatic AgentsArthritis, PsoriaticArthritis, RheumatoidBetacoronavirusBiological ProductsCoronavirus InfectionsCOVID-19FemaleGlucocorticoidsHospitalizationHumansJanus Kinase InhibitorsLupus Erythematosus, SystemicMaleMiddle AgedMultivariate AnalysisPandemicsPneumonia, ViralPrednisoneProtective FactorsRegistriesRheumatic DiseasesRisk FactorsSARS-CoV-2Severity of Illness IndexSpondylarthropathiesTumor Necrosis Factor InhibitorsVasculitisYoung AdultConceptsDisease-modifying antirheumatic drugsRheumatic diseasesHospitalisation statusHigher oddsNon-steroidal anti-inflammatory drug useConventional disease-modifying antirheumatic drugsAnti-inflammatory drug useOdds of hospitalisationRheumatic disease diagnosisRheumatic disease medicationsMultivariable-adjusted modelsMultivariable logistic regressionJanus kinase inhibitorCOVID-19 outcomesCOVID-19Prednisone doseAntirheumatic drugsGlucocorticoid exposureInhibitor useAntimalarial useClinical factorsCase seriesSmoking statusReduced oddsDecreased odds